Table 18

Comparisons of rosiglitazone to sulfonylureas for the outcomes of hypoglycemic events, functional status, and quality of life

StudyDosageComparison sulfonylureaIncidence of hypoglycemic events (% of patients with an event)Functional status HRQLStudy quality
Baski A 20042254 mg twice daily + gliclazide 160 mg dailyGliclazide 160 mg dailyRosi: 6% total; 1% severe
Gliclazide: 2% total; 0.4% severe
Definition: Inability to perform normal daily activities
NR
NR
Fair
Kerenyi A 20042278 mg daily + glibenclamide 7.5 mg dailyGlibenclamide 7.5 – 15 mg dailyRosi + glibenclamide: 18.5% total; 0.6%; 6/165 withdrawals for hypoglycemia
Glibenclamide: 4.1% total; 0% severe; no withdrawals for hypoglycemia
NR
NR
Fair
St John Sutton M 20022244 mg twice dailyGlyburide mean 10.5 mg dailyRosi: 1.9% had signs or symptoms; none required treatment
Glyburide: 7.1% (3/7 required treatment); no withdrawals
NR
NR
Fair
Vongthavaravat
V 2002226
2 mg twice daily + various SUVarious SURosi: 11.6% total; severe in 1/19 episodes
SU: 1.2% total; 0% severe Between-group P <0.001
NR
NR
Fair

Abbreviations: NR, not reported; SU, sulfonylurea; rosi, rosiglitazone.

From: Results

Cover of Drug Class Review: Thiazolidinediones
Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].
Norris SL, Carson S, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2008 Aug.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.